FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3136138507> ?p ?o ?g. }

• W3136138507 endingPage "101046" @default.
• W3136138507 startingPage "101046" @default.
• W3136138507 abstract "The epithelial to mesenchymal transition (EMT) is characterized by a loss of cell polarity, a decrease in the epithelial cell marker E-cadherin, and an increase in mesenchymal markers including the zinc-finger E-box binding homeobox (ZEB1). The EMT is also associated with an increase in cell migration and anchorage-independent growth. Induction of a reversal of the EMT, a mesenchymal to epithelial transition (MET), is an emerging strategy being explored to attenuate the metastatic potential of aggressive cancer types, such as triple-negative breast cancers (TNBCs) and tamoxifen-resistant (TAMR) ER-positive breast cancers, which have a mesenchymal phenotype. Patients with these aggressive cancers have poor prognoses, quick relapse, and resistance to most chemotherapeutic drugs. Overexpression of extracellular signal-regulated kinase (ERK) 1/2 and ERK5 is associated with poor patient survival in breast cancer. Moreover, TNBC and tamoxifen resistant cancers are unresponsive to most targeted clinical therapies and there is a dire need for alternative therapies. In the current study, we found that MAPK3, MAPK1, and MAPK7 gene expression correlated with EMT markers and poor overall survival in breast cancer patients using publicly available datasets. The effect of ERK1/2 and ERK5 pathway inhibition on MET was evaluated in MDA-MB-231, BT-549 TNBC cells, and tamoxifen-resistant MCF-7 breast cancer cells. Moreover, TU-BcX-4IC patient-derived primary TNBC cells were included to enhance the translational relevance of our study. We evaluated the effect of pharmacological inhibitors and lentivirus-induced activation or inhibition of the MEK1/2-ERK1/2 and MEK5-ERK5 pathways on cell morphology, E-cadherin, vimentin and ZEB1 expression. Additionally, the effects of pharmacological inhibition of trametinib and XMD8-92 on nuclear localization of ERK1/2 and ERK5, cell migration, proliferation, and spheroid formation were evaluated. Novel compounds that target the MEK1/2 and MEK5 pathways were used in combination with the AKT inhibitor ipatasertib to understand cell-specific responses to kinase inhibition. The results from this study will aid in the design of innovative therapeutic strategies that target cancer metastases." @default.
• W3136138507 created "2021-03-29" @default.
• W3136138507 creator A5001720770 @default.
• W3136138507 creator A5020539295 @default.
• W3136138507 creator A5026020049 @default.
• W3136138507 creator A5033515329 @default.
• W3136138507 creator A5041222618 @default.
• W3136138507 creator A5041301571 @default.
• W3136138507 creator A5047042859 @default.
• W3136138507 creator A5048983251 @default.
• W3136138507 creator A5067088371 @default.
• W3136138507 creator A5076152468 @default.
• W3136138507 creator A5083785482 @default.
• W3136138507 date "2021-06-01" @default.
• W3136138507 modified "2023-10-14" @default.
• W3136138507 title "Diverse and converging roles of ERK1/2 and ERK5 pathways on mesenchymal to epithelial transition in breast cancer" @default.
• W3136138507 cites W1922475963 @default.
• W3136138507 cites W1966030922 @default.
• W3136138507 cites W1969333995 @default.
• W3136138507 cites W1979067350 @default.
• W3136138507 cites W1980023088 @default.
• W3136138507 cites W2012584321 @default.
• W3136138507 cites W2014691022 @default.
• W3136138507 cites W2023384375 @default.
• W3136138507 cites W2050831491 @default.
• W3136138507 cites W2051541007 @default.
• W3136138507 cites W2056928766 @default.
• W3136138507 cites W2072642940 @default.
• W3136138507 cites W2080232352 @default.
• W3136138507 cites W2083411591 @default.
• W3136138507 cites W2135967835 @default.
• W3136138507 cites W2136921951 @default.
• W3136138507 cites W2139205106 @default.
• W3136138507 cites W2140551998 @default.
• W3136138507 cites W2141715168 @default.
• W3136138507 cites W2150670229 @default.
• W3136138507 cites W2154589460 @default.
• W3136138507 cites W2170242482 @default.
• W3136138507 cites W2478846246 @default.
• W3136138507 cites W2509675510 @default.
• W3136138507 cites W2524435562 @default.
• W3136138507 cites W2582457346 @default.
• W3136138507 cites W2593112691 @default.
• W3136138507 cites W2800106575 @default.
• W3136138507 cites W2803396110 @default.
• W3136138507 cites W2891700678 @default.
• W3136138507 cites W2959432596 @default.
• W3136138507 cites W3012485400 @default.
• W3136138507 cites W3016840787 @default.
• W3136138507 cites W3016994894 @default.
• W3136138507 cites W3047511733 @default.
• W3136138507 cites W3104962360 @default.
• W3136138507 doi "https://doi.org/10.1016/j.tranon.2021.101046" @default.
• W3136138507 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8020482" @default.
• W3136138507 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33761370" @default.
• W3136138507 hasPublicationYear "2021" @default.
• W3136138507 type Work @default.
• W3136138507 sameAs 3136138507 @default.
• W3136138507 citedByCount "3" @default.
• W3136138507 countsByYear W31361385072021 @default.
• W3136138507 countsByYear W31361385072022 @default.
• W3136138507 countsByYear W31361385072023 @default.
• W3136138507 crossrefType "journal-article" @default.
• W3136138507 hasAuthorship W3136138507A5001720770 @default.
• W3136138507 hasAuthorship W3136138507A5020539295 @default.
• W3136138507 hasAuthorship W3136138507A5026020049 @default.
• W3136138507 hasAuthorship W3136138507A5033515329 @default.
• W3136138507 hasAuthorship W3136138507A5041222618 @default.
• W3136138507 hasAuthorship W3136138507A5041301571 @default.
• W3136138507 hasAuthorship W3136138507A5047042859 @default.
• W3136138507 hasAuthorship W3136138507A5048983251 @default.
• W3136138507 hasAuthorship W3136138507A5067088371 @default.
• W3136138507 hasAuthorship W3136138507A5076152468 @default.
• W3136138507 hasAuthorship W3136138507A5083785482 @default.
• W3136138507 hasBestOaLocation W31361385071 @default.
• W3136138507 hasConcept C121608353 @default.
• W3136138507 hasConcept C126322002 @default.
• W3136138507 hasConcept C142724271 @default.
• W3136138507 hasConcept C143998085 @default.
• W3136138507 hasConcept C184235292 @default.
• W3136138507 hasConcept C198826908 @default.
• W3136138507 hasConcept C2777176818 @default.
• W3136138507 hasConcept C2779013556 @default.
• W3136138507 hasConcept C2780110267 @default.
• W3136138507 hasConcept C502942594 @default.
• W3136138507 hasConcept C530470458 @default.
• W3136138507 hasConcept C57074206 @default.
• W3136138507 hasConcept C71924100 @default.
• W3136138507 hasConcept C76419328 @default.
• W3136138507 hasConcept C86803240 @default.
• W3136138507 hasConcept C95444343 @default.
• W3136138507 hasConceptScore W3136138507C121608353 @default.
• W3136138507 hasConceptScore W3136138507C126322002 @default.
• W3136138507 hasConceptScore W3136138507C142724271 @default.
• W3136138507 hasConceptScore W3136138507C143998085 @default.
• W3136138507 hasConceptScore W3136138507C184235292 @default.
• W3136138507 hasConceptScore W3136138507C198826908 @default.
• W3136138507 hasConceptScore W3136138507C2777176818 @default.

• next